HC Wainwright Forecasts Weaker Earnings for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – Investment analysts at HC Wainwright decreased their Q2 2025 EPS estimates for shares of Kodiak Sciences in a report issued on Monday, May 19th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.09) per share for the quarter, down from their previous forecast of ($0.99). HC Wainwright currently has a “Neutral” rating and a $3.00 target price on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($4.36) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($4.20) EPS, FY2028 earnings at ($2.97) EPS and FY2029 earnings at ($1.56) EPS.

Kodiak Sciences Stock Up 9.4%

KOD stock opened at $4.06 on Wednesday. The company has a market cap of $214.22 million, a price-to-earnings ratio of -1.11 and a beta of 2.42. The business has a fifty day simple moving average of $3.29 and a 200-day simple moving average of $5.49. Kodiak Sciences has a 52 week low of $1.92 and a 52 week high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.20).

Institutional Investors Weigh In On Kodiak Sciences

A number of institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its holdings in shares of Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock worth $32,000 after purchasing an additional 2,988 shares during the period. US Bancorp DE purchased a new stake in shares of Kodiak Sciences during the 4th quarter worth about $40,000. Headlands Technologies LLC purchased a new position in Kodiak Sciences in the fourth quarter valued at approximately $90,000. Vontobel Holding Ltd. acquired a new position in Kodiak Sciences during the first quarter valued at approximately $28,000. Finally, Fox Run Management L.L.C. acquired a new position in Kodiak Sciences during the fourth quarter valued at approximately $118,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.